Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 40 of 59, showing 10 Applications out of 584 total, starting on record 391, ending on 400

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

391.

ECCT/23/04/05   BiMVaC01
    A randomised, controlled clinical trial to assess and compare the immunogenicity, safety and reactogenicity of the bivalent Omicron BA.4/BA.5 adapted, and the original Wuhan-Hu-1-strain, BNT162b2 COVID-19 vaccine formulations in healthy unvaccinated East African adults.   
Principal Investigator(s)
1. NDUNGU FRANCIS
2. Said Jongo
Site(s) in Kenya
KEMRI-CGMRC Kilifi
 
06-07-2023 View

392.

ECCT/25/09/03   PRESERVE
    Partial breast re-irradiation using ultra hypofractionation (PRESERVE) Phase 2 multi-institutional study   
Principal Investigator(s)
1. Angela Waweru
Site(s) in Kenya
Aga Khan University Hospital
 
09-02-2026 View

393.

ECCT/15/02/03   IVERMAL study
    Efficacy and safety of high-dose Ivermectin for reducing malaria transmission: A dose finding study   
Principal Investigator(s)
1. Menno Roderick Smit
Site(s) in Kenya
1. Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH) (Kisumu county)
2. Kisumu District Hospital (KDH), (Kisumu county)
3. Siaya District Hospital (Siaya county)
4. Vihiga District Hospital (Vihiga county)
 
26-03-2015 View

394.

ECCT/11/12/04   PENNVAX-G DNA/MVA HIV Vaccine Phase 1 trial
    A Phase I Study of the Safety and Immunogenicity of PENNVAX™-G DNA (Env & Gag) Administered by Intramuscular Biojector® 2000 or by CELLECTRA® Intramuscular Electroporation Device Followed by MVACMDR (HIV-1 CM235 env/ CM240 gag/pol) Boost in Healthy, HIV Uninfected Adults   
Principal Investigator(s)
1. FREDRICK KIPYEGO SAWE
Site(s) in Kenya
KEMRI/Walter Reed Project-Kericho
 
15-02-2013 View

395.

ECCT/20/06/06   E-MOTIVE FORMATIVE
    Understanding effectiveness of implementation of a postpartum haemorrhage initial response bundle   
Principal Investigator(s)
1. Zahida Qureshi
Site(s) in Kenya
1. Mwingi Sub county (level 4 ) hospital (Kitui county)
2. Nyeri Level 5 Hospital (Nyeri county)
3. Garissa county referral hospital (Garissa county)
4. Embu Level 5 hospital (Embu county)
5. TIGONI LEVEL 4 HOSPTIAL (Kiambu county)
6. Meru Teaching and Referral Hospital (Meru county)
7. Kitengela Sub county Hospital (Kajiado county)
8. Kakamega County Government Referral Hospital (Kakamega county)
9. Mbagathi County Hospital (Nairobi City county)
10. St. Mary\'s Mission Hospital (Nairobi City county)
 
15-10-2020 View

396.

ECCT/20/06/08   E-MOTIVE TRIAL
    Early detection of PPH and treatment using the WHO MOTIVE ‘first response’ bundle: a cluster randomised trial with health economic analysis and mixed-methods evaluation.           
Principal Investigator(s)
1. Zahida Qureshi
Site(s) in Kenya
1. Mwingi Sub county (level 4 ) hospital (Kitui county)
2. Nyeri Level 5 Hospital (Nyeri county)
3. Garissa county referral hospital (Garissa county)
4. Embu Level 5 hospital (Embu county)
5. TIGONI LEVEL 4 HOSPTIAL (Kiambu county)
6. Meru Teaching and Referral Hospital (Meru county)
7. Kitengela Sub county Hospital (Kajiado county)
8. Kakamega County Government Referral Hospital (Kakamega county)
9. Mbagathi County Hospital (Nairobi City county)
10. St. Mary\'s Mission Hospital (Nairobi City county)
 
19-10-2020 View

397.

ECCT/19/01/02   Opt4Kids
    Optimizing viral load suppression in Kenyan children on antiretroviral therapy (Opt4Kids)   
Principal Investigator(s)
1. Lisa Dillabaugh Abuogi
2. Patrick Oyaro Owiti
Site(s) in Kenya
1. Kisumu County Hospital (Kisumu county)
2. Ahero County Hospital (Kisumu county)
3. Nyakach County Hospital (Kisumu county)
4. Lumumba sub-County Hospital (Kisumu county)
5. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county)
 
15-03-2019 View

398.

ECCT/18/04/01   CKAF156 STUDY
    A Phase 2 interventional, multicenter, randomized open-label study to determine the effective and tolerable dose of KAF156 and Lumefantrine Solid Dispersion Formulation in combination, given once daily for 1, 2 and 3-days to adults and children with uncomplicated Plasmodium falciparum malaria.   
Principal Investigator(s)
1. Bernhards Ogutu
Site(s) in Kenya
1. KEMRI CDC (Siaya county)
2. Walter Reed Project (Kisumu county)
 
23-08-2018 View

399.

ECCT/25/08/02   MK-8527-010
    A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis in Women.   
Principal Investigator(s)
1. Elizabeth Anne Bukusi
Site(s) in Kenya
1. KEMRI CMR RCTP (Kisumu county)
 
21-11-2025 View

400.

ECCT/24/01/01   SAVIS
    A Phase 1 Clinical Study to Evaluate the Safety and Immunogenicity of a Novel GMMA Vaccine Against Invasive Non-Typhoidal Salmonella in healthy Kenyan adults.      
Principal Investigator(s)
1. ANTHONY SCOTT
Site(s) in Kenya
KEMRI Centre for Geographical Medicine Research Coast
 
15-04-2024 View